MedTrace Logo

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults

NCT05219968 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2025-05-02

Study results available
· View outcomes & findings →

Summary

Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.

Conditions

  • Chronic Sinusitis
  • Chronic Rhinosinusitis (Diagnosis)

Interventions

DRUG

LYR-210

LYR-210 drug matrix (mometasone furoate)

DRUG

Sham procedure control

Sham procedure control

OTHER

Background Therapy

Daily Saline Irrigation

Sponsors & Collaborators

  • Lyra Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2024-03-04
Completion
2024-09-16
FDA Drug
Yes

Countries

  • United States
  • Austria
  • Czechia
  • Poland
  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05219968 on ClinicalTrials.gov